Reyvow

Description

Reyvow (lasmiditan)

Background
Reyvow is a highly selective 5-HT₁F receptor agonist is indicated for the treatment of migraines in adults with or without aura. Reyvow works through binding to serotonin receptors in the brain to decrease activation and sensitization of the trigeminal nerve system within the meninges. Unlike other serotonergic agonists for migraines, Reyvow does not activate 5-HT₁B receptors in peripheral blood vessels, including coronary arteries that have caused life-threatening disturbances in cardiac rhythm and myocardial infarction(1-2).

Regulatory Status
FDA-approved indication: Reyvow tablets are indicated for the acute treatment of migraine attacks with or without aura in adults (2).

Limitations of Use: Reyvow should only be used if a clear diagnosis of migraine has been established. Reyvow is not indicated for the preventative treatment of a migraine. A second dose of Reyvow in a 24 hour period has not been shown to be effective for the same migraine attack. The safety of treating an average of more than 4 migraine attacks in a 30-day period has not been established (2).

This class of medications has potentially serious side effects, especially when taken more than recommended. Serotonin syndrome was reported in patients who were not taking any other serotonergic medications. Coadministration of Reyvow with other serotonergic drugs [selective
section: Prescription Drugs  
subsection: Analgesics and Anesthetics  
subject: Reyvow  

eroton reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase (MAO) inhibitors] may also lead to serotonin syndrome. Excessive use of Reyvow can lead to medication overuse headache and detoxification of patients including treatment of withdrawal symptoms may be necessary. Overuse of any acute migraine drug (ergotamines, triptans, opioids, or a combination of these drugs for 10 or more days per month) may lead to an exacerbation headache. Driving impairment and central nervous system depression including dizziness and sedation have been found in patients taking Reyvow. Vital sign changes including heart rate decrease and blood pressure increase have also been reported (2).

Reyvow should not be taken unless the patient can wait at least 8 hours between dosing and driving or operating machinery (2).

Reyvow inhibits P-gp and breast cancer resistant protein (BCRP) in vitro. Concomitant use of Reyvow and drugs that are P-gp or BCRP substrates should be avoided (2).

The safety and effectiveness of Reyvow in pediatric patients has not been established (2).

Related policies
Amerge, Axert, Butalbital analgesics, Frova, Maxalt, Migraine Calcitonin Gene Related Peptide (CGRP) Antagonists, Migraine Powders, Migranal Nasal Spray, Relpax, Sumatriptan, Sumatriptan Injection, Zomig

Policy
This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.

Reyvow may be considered medically necessary for the treatment of migraine with or without aura (classic or common) and if the conditions indicated below are met.

Reyvow is considered investigational for patients less than 18 years of age and for all other indications.

Prior-Approval Requirements
Age 18 years of age or older

Diagnoses
Patient must have **ONE** of the following:

1. Migraine, with aura (classic)
2. Migraine, without aura (common)

**AND ALL** of the following:

a. Inadequate treatment response, intolerance, or contraindication to at least **TWO** triptan agents
b. Prescriber agrees to advise patient not to drive or operate machinery for at least 8 hours after taking Reyvow
c. **NO** severe hepatic impairment (Child-Pugh Class C)
d. **NO** dual therapy with a triptan agent at prior authorization quantities

### Prior-Approval Renewal Requirements

**Age**

18 years of age or older

**Diagnoses**

Patient must have **ONE** of the following:

1. Migraine, with aura (classic)
2. Migraine, without aura (common)

**AND ALL** of the following:

a. Prescriber agrees to advise patient not to drive or operate machinery for at least 8 hours after taking Reyvow
b. **NO** severe hepatic impairment (Child-Pugh Class C)
c. **NO** dual therapy with a triptan agent at prior authorization quantities

### Policy Guidelines

**Pre - PA Allowance**

None

**Prior - Approval Limits**

**Quantity**

24 tablets per 90 days

**Duration**

6 months
Prior – Approval Renewal Limits
Same as above

Rationale

Summary
Reyvow tablets are indicated for the acute treatment of migraine attacks with or without aura in adults. Reyvow is not indicated for the preventative treatment of a migraine. The safety of treating an average of more than 4 migraine attacks in a 30-day period has not been established. This medication has potentially serious side effects, including serotonin syndrome, CNS depression, driving impairment, and medication overuse headache. The safety and effectiveness of Reyvow in pediatric patients has not been established (1-2).

Prior authorization is required to ensure the safe, clinically appropriate and cost effective use of Reyvow while maintaining optimal therapeutic outcomes.

References

Policy History

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>November 2019</td>
<td>New Addition</td>
</tr>
<tr>
<td>December 2019</td>
<td>Annual review</td>
</tr>
</tbody>
</table>

Keywords

This policy was approved by the FEP® Pharmacy and Medical Policy Committee on December 6, 2019 and is effective January 1, 2020.